GSK
Price
$36.20
Change
-$0.28 (-0.77%)
Updated
Jul 18, 04:02 PM (EDT)
Capitalization
88.13B
12 days until earnings call
SNY
Price
$48.28
Change
-$0.37 (-0.76%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
122.61B
13 days until earnings call
Interact to see
Advertisement

GSK vs SNY

Header iconGSK vs SNY Comparison
Open Charts GSK vs SNYBanner chart's image
GSK
Price$36.20
Change-$0.28 (-0.77%)
Volume$2.75K
Capitalization88.13B
Sanofi ADS
Price$48.28
Change-$0.37 (-0.76%)
Volume$25.7K
Capitalization122.61B
GSK vs SNY Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. SNY commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and SNY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (GSK: $36.47 vs. SNY: $48.65)
Brand notoriety: GSK and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 284% vs. SNY: 79%
Market capitalization -- GSK: $88.13B vs. SNY: $122.61B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, GSK is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 3 TA indicator(s) are bullish while SNY’s TA Score has 3 bullish TA indicator(s).

  • GSK’s TA Score: 3 bullish, 5 bearish.
  • SNY’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both GSK and SNY are a good buy in the short-term.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -7.86% price change this week, while SNY (@Pharmaceuticals: Major) price change was -1.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.97%. For the same industry, the average monthly price growth was +3.29%, and the average quarterly price growth was +10.80%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

SNY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.97% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than GSK($88.1B). SNY has higher P/E ratio than GSK: SNY (20.80) vs GSK (14.01). GSK YTD gains are higher at: 10.277 vs. SNY (5.341). SNY has higher annual earnings (EBITDA): 12.6B vs. GSK (9.08B). SNY has more cash in the bank: 8.98B vs. GSK (4.99B). GSK (18B) and SNY (18.4B) have identical debt. SNY has higher revenues than GSK: SNY (46.4B) vs GSK (30.3B).
GSKSNYGSK / SNY
Capitalization88.1B123B72%
EBITDA9.08B12.6B72%
Gain YTD10.2775.341192%
P/E Ratio14.0120.8067%
Revenue30.3B46.4B65%
Total Cash4.99B8.98B56%
Total Debt18B18.4B98%
FUNDAMENTALS RATINGS
GSK vs SNY: Fundamental Ratings
GSK
SNY
OUTLOOK RATING
1..100
6074
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
7972
SMR RATING
1..100
4175
PRICE GROWTH RATING
1..100
5459
P/E GROWTH RATING
1..100
2489
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (8) in the Pharmaceuticals Major industry is in the same range as SNY (8). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.

SNY's Profit vs Risk Rating (72) in the Pharmaceuticals Major industry is in the same range as GSK (79). This means that SNY’s stock grew similarly to GSK’s over the last 12 months.

GSK's SMR Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (75). This means that GSK’s stock grew somewhat faster than SNY’s over the last 12 months.

GSK's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as SNY (59). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.

GSK's P/E Growth Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (89). This means that GSK’s stock grew somewhat faster than SNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKSNY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
51%
Bearish Trend 2 days ago
45%
Momentum
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
52%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 9 days ago
58%
Bullish Trend 2 days ago
51%
Declines
ODDS (%)
Bearish Trend 16 days ago
53%
Bearish Trend 4 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BFOR78.300.86
+1.12%
Barron's 400 ETF
SMDV66.530.49
+0.74%
ProShares Russell 2000 Dividend Growers
RBUF27.700.09
+0.33%
Innovator U.S. Small Cp 10 Buf ETF - Qt
GOLY29.10-0.07
-0.24%
Strategy Shares Gold-Hedged Bond ETF
INDA55.01-0.26
-0.47%
iShares MSCI India ETF